Researchers at the University of Dundee, who last year identified the gene that causes eczema and associated forms of asthma, have now discovered that defects on the same gene can drastically affect the day-to-day management of asthma in millions of children and young adults.
Their findings apply to about 1 in 4 of all asthma patients, who show a particular gene defect. The most seriously affected sufferers are those with a defect on both copies of the gene, which occurs in only about 1 in 100 asthma patients.
The genetic defect can make asthma sufferers three to six times more likely to have to reach out for their inhaler every day.
The Dundee team announced last year that they had identified a gene that produces the protein filaggrin, which is normally found in large quantities in the outermost layers of the skin and is essential in providing a protective layer which keeps water in and foreign organisms out.
In people with filaggrin mutations, foreign substances can easily enter the skin and be seen by the immune system. This explains the development of inflamed skin (eczema). In some people, priming of the immune system through the “leaky” skin can lead to asthma when foreign substances later enter the lungs.
Since making their initial discovery the Dundee researchers have continued their work on identifying how the filaggrin gene works and the effects its behaviour has.
Now the team of asthma physician Dr. Somnath Mukhopadhyay, scientist Dr. Colin Palmer and genetic skin disease expert Professor Irwin McLean has identified how the gene can determine the amount of treatment that a child or young adult with asthma needs on a day-to-day basis.
In a new paper published in The Journal of Allergy and Clinical Immunology, they show defects in the gene can make asthma patients three to six times more likely to have to reach out for their inhaler every day. These patients are similarly more likely to need extra medicines on top of inhaled steroids to control their asthma.
?Our findings show that these gene defects that affect the skin barrier which filaggrin provides has a significant effect on day-to-day asthma morbidity and medication use,? said Dr Mukhopadhyay.
?If these genetic skin barrier defects directly exacerbate asthma, young asthma sufferers who show these barrier defects may respond better to allergen withdrawal strategies, which would lead to a significant long-term reduction in asthma medication requirements.?
The need for controller and reliever medicines drives the lifestyles of millions of young asthmatics in the UK and abroad, many of whom have to use their `blue inhaler?, the commonest ?reliever? asthma medicine, combined with top-up ?controller? asthma treatments.
Eczema and asthma are common and serious diseases in children and young adults in the United Kingdom.
The research was made possible through the support of child patients with asthma in Tayside and their parents, and the support offered by the general practitioners from Dundee, Perth and Kinross, Angus and Fife.
The clinical work in Scotland was supported by the Scottish Executive through Scottish Enterprise Tayside, The Gannochy Trust in Perth and Perth and Kinross Council. The laboratory work was funded by The Wellcome Trust and the skin disease charities DEBRA, PC Project, British Skin Foundation and National Eczema Society.